Follow-The-Filings

Security · featured owners

RARE Ultragenyx Pharmaceutical In

COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 5.0%
  • $35M
  • 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 5.0% (Michael Krensavage - Kren...) · not free-float ownership

  1. Michael Krensavage 5.0%
  2. Palo Alto Investors 2.8%
  3. Nathan Fischel reduce 0.30%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Palo Alto Investors 2026 Q2 2.8% Hold 596,495 $20M history
Michael Krensavage - Krensavage Asset Management 2026 Q2 5.0% Hold 390,879 $13M history
Nathan Fischel - Dafna Capital Management 2026 Q2 0.30% Reduce −22.9% 47,100 $2M history

3 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $434.25M $560.23M $673M
Net income -$606.64M -$569.18M -$575M
Net margin * -139.7% -101.6% -85.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $732.18M $817.12M $951M
Total non-current assets * $758.83M $686.33M $581M
Total assets $1.49B $1.5B $1.53B
Total current liabilities $280.44M $344.15M $384M
Total non-current liabilities * $935.16M $897.01M $1.22B
Total equity $275.41M $255.3M -$80M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$474.81M -$414.19M -$466M
Cash from investing $168M -$17.77M $236M
Cash from financing $388.14M $399.24M $478M
Net change in cash $81.8M -$35.24M $252M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders